Uniting All Regulatory Stakeholders Navigating the Complex, Ever-Evolving Global Landscape

There is a crucial need to add clarity to companion diagnostic (CDx) regulation; from IVDR in Europe, to LDT regulation in the US, to complicated reimbursement dynamics in APAC, confusing and impractical regulatory requirements are slowing the momentum of clinical trials and preventing patients with unmet access to best-in-class drugs.

Enter the inaugural World CDx Regulatory Affairs & Policy Summit. This is the pioneering platform singularly focused on uniting regulatory experts, payers, policymakers, drug developers and diagnostic providers to address key challenges, form alliances and outline future policy and strategy directions. The goal? A streamlined approach to regulatory bodies to allow patients timely access to diagnostic tests globally.

Gathering experts from USA, Europe and APAC, this forum is your opportunity to be in the room with Directors, VPs, and SVPs from Regulation, Policy, Reimbursement, Companion Diagnostics at Merck, Pfizer, Sanofi and more. Join them in a mission to harmonize and align requirements across regions through new policies, secure reimbursement and achieve global market access faster.

Secure your spot to join 80+ senior decision makers at the first and only industry-led regulatory and policy forum for companion diagnostics this June to manifest new policies that expedite both clinical trial initiation, and approvals of drug-diagnostics to allow patients around the World access to safe, effective and affordable diagnostic tests.